Канал: BenevolentAI

Innovation in AI for Target Identification & Drug Discovery, Anne Phelan, CSO BenevolentAI

Innovation in AI for Target Identification & Drug Discovery, Anne Phelan, CSO BenevolentAI

How can industry and government collaborate effectively to promote AI adoption?

How can industry and government collaborate effectively to promote AI adoption?

Using large language models to discover novel drug targets · Nicola Richmond, VP AI BenevolentAI

Using large language models to discover novel drug targets · Nicola Richmond, VP AI BenevolentAI

BenevolentAI: Company Overview by Joanna Shields, CEO

BenevolentAI: Company Overview by Joanna Shields, CEO

#BenevolentResearch · On Masked Language Models for Contextual Link Prediction

#BenevolentResearch · On Masked Language Models for Contextual Link Prediction

BenevolentAI’s Innovation Week: pushing the boundaries of AI in drug discovery

BenevolentAI’s Innovation Week: pushing the boundaries of AI in drug discovery

#BenevolentResearch · Improving data integration, counterfactual inference & fairness · ICML 2022

#BenevolentResearch · Improving data integration, counterfactual inference & fairness · ICML 2022

#WEF22 | Unlocking the Power of Digital Health w/ Joanna Shields | Davos

#WEF22 | Unlocking the Power of Digital Health w/ Joanna Shields | Davos

BenevolentAI · AI-Enabled Drug Discovery

BenevolentAI · AI-Enabled Drug Discovery

#InternAtBenevolent: life as a tech intern at BenevolentAI

#InternAtBenevolent: life as a tech intern at BenevolentAI

Joanna Shields • J.P. Morgan Health Care Conference 2022

Joanna Shields • J.P. Morgan Health Care Conference 2022

#BenevolentResearch: Directed Graph Embeddings in Pseudo-Riemannian Manifolds

#BenevolentResearch: Directed Graph Embeddings in Pseudo-Riemannian Manifolds

#GBMDay: An AI-Enabled Approach to GBM Drug Discovery

#GBMDay: An AI-Enabled Approach to GBM Drug Discovery

BenevolentAI & AstraZeneca: identifying novel targets for chronic kidney disease

BenevolentAI & AstraZeneca: identifying novel targets for chronic kidney disease

BenevolentAI & AstraZeneca: finding novel targets for idiopathic pulmonary fibrosis

BenevolentAI & AstraZeneca: finding novel targets for idiopathic pulmonary fibrosis

BenevolentAI & AstraZeneca: Fusing AI and Drug Discovery Expertise to Find New Treatments for CKD

BenevolentAI & AstraZeneca: Fusing AI and Drug Discovery Expertise to Find New Treatments for CKD

Women In Tech Meetup: Working in ML Applied Drug Discovery

Women In Tech Meetup: Working in ML Applied Drug Discovery

How do we get the next 10 years right? | CogX Opening Keynote w/ Joanna Shields

How do we get the next 10 years right? | CogX Opening Keynote w/ Joanna Shields

Federating data to create rich longitudinal datasets

Federating data to create rich longitudinal datasets

Data Diversity Initiative launch highlights: why is data diversity so important?

Data Diversity Initiative launch highlights: why is data diversity so important?

Ensuring data sources accurately reflect the patient population

Ensuring data sources accurately reflect the patient population

Making Data Diversity a Cultural Norm

Making Data Diversity a Cultural Norm

Data Diversity Initiative: Tackling the Medical Research Data Gap

Data Diversity Initiative: Tackling the Medical Research Data Gap

Charting the progress of BenevolentAI’s collaboration with AstraZeneca

Charting the progress of BenevolentAI’s collaboration with AstraZeneca

Break-Out Week: a space for creative thinking

Break-Out Week: a space for creative thinking

Challenges of designing an AI platform for Drug Discovery w/ Marek Kultys

Challenges of designing an AI platform for Drug Discovery w/ Marek Kultys

SXSW Series | Episode 4 - Patient Stratification in Target ID , OMICS data

SXSW Series | Episode 4 - Patient Stratification in Target ID , OMICS data

SXSW Series | Episode 5 - Next steps: From molecule design to medicine

SXSW Series | Episode 5 - Next steps: From molecule design to medicine

SXSW Serie | Episode 1 - Designing better medicines using AI and big data

SXSW Serie | Episode 1 - Designing better medicines using AI and big data

SXSW Series | Episode 2 - Building a Disease Specific Knowledge Base

SXSW Series | Episode 2 - Building a Disease Specific Knowledge Base

SXSW Series | Episode 3 - Target Identification, Literature Knowledge Inference

SXSW Series | Episode 3 - Target Identification, Literature Knowledge Inference

AI: The Next Revolution In Medicine?

AI: The Next Revolution In Medicine?

BenevolentAI team offsite, Cambridge June 2018

BenevolentAI team offsite, Cambridge June 2018

Artificial Intelligence in Bioscience Symposium 2017 highlights

Artificial Intelligence in Bioscience Symposium 2017 highlights

#BIOAI2017 John Fox, Oxford University : Data science meets knowledge engineering

#BIOAI2017 John Fox, Oxford University : Data science meets knowledge engineering

#BIOAI2017 What does cultural and societal engagement with AI look like?

#BIOAI2017 What does cultural and societal engagement with AI look like?

#BIOAI2017 Jose Miguel Lobato: Advances in deep generative models of chemical compounds

#BIOAI2017 Jose Miguel Lobato: Advances in deep generative models of chemical compounds

#BIOAI2017 Navin Ramachandran, UCLH: Issues to consider in adopting AI?

#BIOAI2017 Navin Ramachandran, UCLH: Issues to consider in adopting AI?

#BIOAI2017 Winston Hide, Sheffield University: Could Machine Learning Ever Cure Alzheimer’s Disease?

#BIOAI2017 Winston Hide, Sheffield University: Could Machine Learning Ever Cure Alzheimer’s Disease?

#BIOAI2017 Slava Akmaev, Berg Health: Artificial Intelligence in Biopharma R&D

#BIOAI2017 Slava Akmaev, Berg Health: Artificial Intelligence in Biopharma R&D

#BIOAI2017 Philippe Sanseau, GSK : Improving drug target selection

#BIOAI2017 Philippe Sanseau, GSK : Improving drug target selection

#BIOAI2017 Suchi Saria, Johns Hopkins: Can machine spot diseases faster than expert humans?

#BIOAI2017 Suchi Saria, Johns Hopkins: Can machine spot diseases faster than expert humans?

#BIOAI2017 Edward Perello, Desktop Genetics: DeskGen AI for CRISPR Genome Editing

#BIOAI2017 Edward Perello, Desktop Genetics: DeskGen AI for CRISPR Genome Editing

#BIOAI2017 Anna Skaya: Improving the logistics behind developing ML models

#BIOAI2017 Anna Skaya: Improving the logistics behind developing ML models

#BIOAI2017 Caswell Barry, UCL: What can AI contribute to Neuroscience?

#BIOAI2017 Caswell Barry, UCL: What can AI contribute to Neuroscience?

#BIOAI2017 Mike Barnes: Endotype discovery & response stratification in Immune-Inflammatory diseases

#BIOAI2017 Mike Barnes: Endotype discovery & response stratification in Immune-Inflammatory diseases